Influvac

Influenza Virus B/Austria/1359417/2021-Like Strain (B/Austria/1359417/2021, Bvr-26) and Influenza A/Vic, the active ingredient in Influvac, is a vaccine presented as an injectable solution for intramuscular or subcutaneous use. It is designed to prevent influenza infection caused by the included viral strains in individuals for whom annual vaccination is recommended, including adults, children, and high‑risk groups.

GNH USA supplies Influvac as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with a focus on quality assurance and regulatory compliance across global markets.

Influvac is a vaccine that targets influenza viruses to provide seasonal protection. Seasonal influenza: induces immunity against the specific B and A strains included, reducing the risk of infection. High‑risk populations: lowers the likelihood of severe influenza complications in elderly, immunocompromised, and pregnant individuals. Children: helps prevent influenza illness in pediatric patients, supporting community herd immunity. Healthcare workers: provides protection to reduce transmission in clinical settings.

Influvac may be associated with a range of post‑vaccination reactions, most of which are mild and transient. Common Side Effects: - Injection site pain, redness or swelling. - Low‑grade fever. - Headache. - Muscle aches. - Fatigue. Serious or Rare Side Effects: - Anaphylaxis or severe allergic reaction. - Guillain‑Barré syndrome. - High fever. - Seizures (rare).

Prior to administering Influvac, healthcare providers should observe several precautionary measures to ensure safety. Allergy assessment: Confirm no severe hypersensitivity to any vaccine component or previous influenza vaccine. Acute illness evaluation: Defer vaccination in individuals with moderate or severe febrile illness until recovery. Immunocompromised status: Recognize that immune response may be reduced; vaccinate but monitor efficacy. Concurrent live vaccines: Avoid administering live attenuated vaccines simultaneously; schedule them separately. Pregnancy consideration: Use only when the potential benefit outweighs any unknown risk; consult obstetric guidance. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Influvac can interact with other medical products, influencing its effectiveness or safety profile. Major Interactions (Avoid): - Severe allergy to vaccine components: contraindicated. - Concurrent administration of live attenuated vaccines: may reduce efficacy of either product. - High‑dose immunoglobulin therapy: can neutralize vaccine antigens and diminish immune response. Moderate Interactions (Monitor Closely): - Antipyretic or analgesic use (e.g., acetaminophen, ibuprofen) around vaccination: may blunt antibody response; monitor. - Other inactivated vaccines given same day: generally safe but observe for additive local reactions. - Immunosuppressive drugs (e.g., corticosteroids, biologics): may lower vaccine-induced immunity; consider timing.